03:53 AM EDT, 09/24/2024 (MT Newswires) -- Takeda Pharmaceutical ( TAK ) said Tuesday it received approval from Japan's Ministry of Health to produce and market its Fruzaqla drug for advanced or recurrent colorectal cancer that cannot be cured or surgically treated and has progressed after chemotherapy.

The approval is based on results from a phase 3 trial that "met all primary and key secondary efficacy endpoints and demonstrated consistent benefits in patients who received Fruzaqla," the company said.

Fruzaqla is approved for marketing in mainland China, Hong Kong and Macau, where it is co-marketed by HUTCHMED ( HCM ) and Eli Lilly (LLY).

Price: 14.63, Change: -0.26, Percent Change: -1.78